Two highly talented researchers from the hematology department were honored by the Sanofi-Aventis-Award 2017. This award was given to Dr. Barbara Peter and Dr. Katharina Blatt from the Ludwig Boltzmann Cluster Oncology coordinated by Prof. Valent, for two publications in renowned scientific journals.
The latest edition of the Blue Book of the WHO, titled the 'Classification of Tumours of Haematopoietic and Lymphoid Tissues', is now available. The basic concept of the classification of mastocytosis has in part been developed in Vienna.
Prof. Peter Valent had the honor to give the Robert Frank Lecture during the opening ceremony of the CED-IADR/NOF Oral Health Resarch Congress on September 21, 2017.
The topic of the lecture was: "Somatic Evolution of Cancer: Cancer Stem Cells and Beyond".
The Ludwig Boltzmann Cluster Oncology (LBC ONC) is happy to welcome the University of Veterinary Medicine Vienna as a new Partner of the Cluster!
In order to celebrate this collaboration, a KickOff Meeting under the motto „Bridging the Gap“ was held.
Aspects of Comparative Oncology relevant to collaborations between the partners of the LBC ONC, including the Vetmeduni Vienna and MedUni Wien were presented.
Several experts from Vienna are represented within the group of leading scientist and top-cited authors in the field of immunology in the German-speaking area. The field of immunology includes many parts of medicine, including allergology, hematology and cancer research. One of the top five cited experts in the field of classic immunology is the scientific coordinator of the LBC ONC, Peter Valent.
The top-citation score is based on the articles from the year 2011 to 2015. Database: 'Web of Science' of the Thomson Reuters-Institute for Scientific Information (ISI).
The Wilhelm Turk Prize of the Austrian Society for Hematology & Medical Oncology (OeGHO) has been awarded to DI. Dr. Katharina Blatt, from the working group of Univ.-Prof. Dr. Peter Valent (Ludwig Boltzmann Cluster Oncology), in the context of the joint annual meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology, which took place in Leipzig in mid-October 2016.
In April 2017 in collaboration with the Medical University of Vienna and the Vienna Cancer Stem Cell Club (VCSCC), members of the Ludwig Boltzmann Cluster Oncology (LBC ONC) organized a Workshop dedicated to erythropoiesis: ´Normal and Neoplastic Erythropoiesis: From Gene Regulation to Targeted Treatment Concepts’. The meeting took place in the Lecture Center (Hörsaal-Zentrum – KR21) of the Medical University of Vienna (General Hospital of Vienna – AKH) on Friday April 28, 2017, from 8:00 AM to 7:00 PM. There will be no registration or registration fee.
It has been known for many years that there are gender-specific risk profiles in various myeloid leukemias, and the prognosis often differs considerably when comparing male and female patient groups. In order to investigate the mechanisms of this phenomenon, the Ludwig-Boltzmann Cluster Oncology has defined a project in which leukemic stem cells and the stem cell niche are to be investigated. The application has been submitted for the Jubilee Fund of the Vienna City Mayor and has recently been approved.
On March 24, 2017, the Comparative Oncology Mast Cell Meeting will be held under the motto "Bridging the Gap" at the Vienna Veterinary University.
National and international experts will present their most recent data on the development of novel therapies for mast cell neoplasms in humans and dogs.
The Comparative Oncology places its efforts in bridging the gap between the veterinary and human medicine, by using synergistic effects of comparative research, in order to improve therapy for humans as well as pets.
This one-day meeting connects scientists from many disciplines - from molecular biology to clinics - and shall present an extensive picture of neoplastic mast cell research and provide an overview of the current targeted therapies available in the veterinary area.
This meeting is free and open to all without prior registration.
The annual meeting of the American Society for Hematology (ASH) was held in San Diego, California, at the beginning of December 2016 (3.12-6.12.2016). A total of 28,000 participants were present (counted), mainly specialist physicians, but also fundamental researchers and representatives of the pharmaceutical industry. Among the countless international experts a strong Austrian participation with numerous oral and poster presentations has been noted. Representatives of the Ludwig Boltzmann Cluster Oncology (LBC ONC) and the Medical University of Vienna (MUV) were also able to present their data during this important meeting, highlighting two register studies in the area of myeloid neoplasms (chronic myelomonocytic leukemia, CMML and mastocytosis).